Keyphrases
Acute Myeloid Leukemia
100%
Anthracyclines
100%
Vosaroxin
100%
Mechanism of Action
40%
Tolerability
40%
Pharmacokinetics
20%
Area Cover
20%
Patient Cohort
20%
First-in-class
20%
Reactive Oxygen Species
20%
Evade
20%
Supportive Care
20%
Monotherapy
20%
Safety Profile
20%
Expert Opinion
20%
Refractory Patients
20%
Pre-clinical and Clinical Trials
20%
Induction Treatment
20%
Clinical Trial Results
20%
P-glycoprotein (P-gp)
20%
Topoisomerase Inhibitors
20%
Cytotoxic Agents
20%
Intermediate-dose Cytarabine
20%
Resistance Pathways
20%
Cytarabine
20%
Relapsed Patients
20%
Topoisomerase Poison
20%
Novel Cytotoxics
20%
Quinolone Derivatives
20%
Topoisomerase II Poison
20%
Older Generation
20%
Pharmacology, Toxicology and Pharmaceutical Science
Vosaroxin
100%
Acute Myeloid Leukemia
100%
Anthracycline
100%
Tolerability
40%
Cytarabine
40%
P-Glycoprotein
20%
Clinical Trial Results
20%
Reactive Oxygen Metabolite
20%
Protein P53
20%
Quinolone Derivative
20%
DNA Topoisomerase
20%
DNA Topoisomerase (ATP Hydrolysing)
20%
Gyrase Inhibitor
20%
Monotherapy
20%
Pharmacokinetics
20%
Diseases
20%
Cytotoxic Agent
20%